Paragraph 4
The manufacturer must conduct all manufacture and assembly operations in such a way as to ensure that the medicinal products to which the F1UK marketing authorisation relates conform with the standards of strength, quality and purity applicable to them under the UK marketing authorisation.
Annotations
Textual amendments
- F1
Word in Sch. 9 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 52(3); 2020 c. 1, Sch. 5 para. 1(1)
Notes on Schedule 9
Textual amendments
- F1
Words in Sch. 9 heading substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 52(2); 2020 c. 1, Sch. 5 para. 1(1)